Dermira Inc. (NASDAQ:DERM) VP Christopher M. Griffith sold 1,303 shares of the business’s stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $33.26, for a total transaction of $43,337.78. Following the transaction, the vice president now directly owns 45,165 shares of the company’s stock, valued at $1,502,187.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of Dermira Inc. (NASDAQ:DERM) opened at 34.47 on Thursday. The stock has a 50 day moving average of $32.40 and a 200-day moving average of $28.50. Dermira Inc. has a 52 week low of $17.42 and a 52 week high of $36.16. The firm’s market capitalization is $1.22 billion.

Dermira (NASDAQ:DERM) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.03. Analysts expect that Dermira Inc. will post ($3.39) earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in shares of Dermira by 6,034.5% in the second quarter. JPMorgan Chase & Co. now owns 3,558 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 3,500 shares during the period. Glenmede Trust Co. NA bought a new stake in shares of Dermira during the second quarter worth $170,000. A.R.T. Advisors LLC bought a new stake in shares of Dermira during the second quarter worth $207,000. DIAM Co. Ltd. bought a new stake in shares of Dermira during the second quarter worth $231,000. Finally, Regents of The University of California bought a new stake in shares of Dermira during the first quarter worth $252,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

A number of research analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating on shares of Dermira in a research note on Wednesday. Leerink Swann reissued a “buy” rating and set a $47.00 target price (up from $46.00) on shares of Dermira in a research note on Thursday, June 2nd. Zacks Investment Research raised shares of Dermira from a “sell” rating to a “hold” rating in a research note on Friday, July 8th. Finally, Wedbush boosted their target price on shares of Dermira from $42.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 2nd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Dermira currently has an average rating of “Buy” and an average price target of $41.00.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

5 Day Chart for NASDAQ:DERM

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.